Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
Supporting Cross-Functional Teams with Corporate-Level Competitive Intelligence
Competitive intelligence in biopharma is typically strong at the asset and indication level but often fragmented at the...
Biopharma entered 2026 with cautious optimism. Where do we stand at the end of the first quarter?
M&A accelerated sharply in March. IPO activity gathered pace before pausing again. Venture capital held steady,...
Loss of exclusivity is accelerating disruption across pharma, putting billions in revenue at risk and testing the limits of traditional forecasting.
As patent cliffs approach, forecasting teams must model not just dec...
Global biopharma alliances reached almost $270bn across 642 deals in 2025, with average disclosed values up 37% year over year. M&A activity generated over $200bn, driven by multiple multi‑billion‑dollar...
Biopharma deal-making rebounded strongly in 2025, with rising confidence, larger transactions, and record alliance values shaping the year.
Our latest Dealmaking Roundup infographic brings together the ke...
Capital returned to biopharma in late 2025, and scrutiny returned with it. In the final quarter, big pharma, biotech, and investors deployed more than £46bn through M&A. Activity increased, but decisions...
